e taxes 3,707 77 -97.9%
Net loss $(40,826) $(60,782) 48.9%
Reconciliation to Credit Agreement
EBITDA:
Operating loss - per above $(37,119) $(60,010)
Adjusted for:
Gain on early extinguishment
of debt (1,329) -
Loss of disposition of assets 945 -
Interest expense, net 32,819 35,911
Depreciation and amortization 11,856 11,254
Goodwill impairment charge 43,600 38,834
Stock compensation expense 632 695
Severance - 2,918
Cost report adjustment 3,871 -
Cost saving initiatives - 3,648
Hospital closure/relocation/
start-up losses 3,198 5,967
Sarbanes Oxley implementation - 1,477
New Orleans operations, net of
proceeds (3,573) 86
Other credit agreement add-back
items 2,850 713
Credit Agreement EBITDA 57,750 41,493
Exercise of cure right for quarter
ended September 30, 2007 - 5,999
Pro Forma Credit Agreement EBITDA $57,750 $47,492
Schedule 3
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
December 31, December 31,
Assets 2006 2007
Current assets:
Cash and cash equivalents $33,250 $17,816
Accounts receivable, net
'/>"/>
SOURCE LifeCare Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine news :1.
LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing2.
LifeCare Holdings, Inc. Announces Third Quarter Results3.
Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources4.
Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market5.
Solera Holdings, Inc. Appoints Jason Brady as General Counsel6.
Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results7.
Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.8.
Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry9.
NightHawk Radiology Holdings, Inc. Announces Board Member Departure10.
NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 200811.
Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds